Drugs / M-Vax
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00257465 | Jun 2005 → Jun 2008 | melanoma | AVAX Technologies | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00477906 | Jul 2016 → Jan 2019 | melanoma | AVAX Technologies | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M-Vax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00477906 ↗ |
| Modality | Vaccine | “a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten)” NCT00257465 ↗ |